Read our MFN preprint: https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two Vital Transformation colleagues on biopharma pricing policy, market access, and innovation risk:
Gwen O'Loughlin: Research Partner at Vital Transformation
Harry Bowen: Consulting Economist at Vital Transformation

They discuss what our new MFN pricing modeling suggests about drug viability, how IRA incentives appear to be reshaping oncology and orphan drug development, why Medicare Advantage and commercial coverage can create administrative friction and delays compared with traditional Medicare, how 340B opacity and consolidation affect the value chain, and what these pressures could mean for insurance premiums, investment, and future innovation.

Key Topics:
MFN Modeling: Net present value analysis, benchmark-country pricing, launch viability, and market uncertainty.
Effects of IRA on Trials: Oncology pullback, small-molecule exposure, orphan drug pressure, and suspended trials.
Coverage Friction: Medicare Advantage burden, prior authorization delays, formulary shifts, and referral slowdowns.
340B Transparency: Vertical integration, hospital consolidation, opaque pricing flows, and revenue pressure.
Innovation Outlook: Premium increases, global competition, intellectual property risk, and future access concerns.

Opinions expressed are those of the speakers.

Read our MFN preprint: <a href="https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/">https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/</a>
In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> speaks with two <a href="https://www.linkedin.com/company/vital-transformation/">Vital Transformation</a> colleagues on biopharma pricing policy, market access, and innovation risk:
<ul>
<li><a href="https://www.linkedin.com/in/gwen-o-loughlin-8792003a9/">Gwen O'Loughlin</a>: Research Partner at <a href="https://www.linkedin.com/company/vital-transformation/">Vital Transformation</a></li>
<li><a href="https://www.linkedin.com/in/harry-p-bowen-10761b31/">Harry Bowen</a>: Consulting Economist at <a href="https://www.linkedin.com/company/vital-transformation/">Vital Transformation</a></li>
</ul>
They discuss what our new MFN pricing modeling suggests about drug viability, how IRA incentives appear to be reshaping oncology and orphan drug development, why Medicare Advantage and commercial coverage can create administrative friction and delays compared with traditional Medicare, how 340B opacity and consolidation affect the value chain, and what these pressures could mean for insurance premiums, investment, and future innovation.
Key Topics:
<ul>
<li>MFN Modeling: Net present value analysis, benchmark-country pricing, launch viability, and market uncertainty.</li>
<li>Effects of IRA on Trials:&nbsp;Oncology pullback, small-molecule exposure, orphan drug pressure, and suspended trials.</li>
<li>Coverage Friction: Medicare Advantage burden, prior authorization delays, formulary shifts, and referral slowdowns.</li>
<li>340B Transparency: Vertical integration, hospital consolidation, opaque pricing flows, and revenue pressure.</li>
<li>Innovation Outlook: Premium increases, global competition, intellectual property risk, and future access concerns.</li>
</ul>
Opinions expressed are those of the speakers.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess, Managing Director of Vital Tran…

Vital Health Podcast

VT's Grumpies and Lady Discuss the U.S. Biotech Policy Landscape

In this best-of edition of the Vital Health Podcast, we revisit two conversations Duane Schulthess has with experts on the future of generic medicines, drug shortages, and supply chain risk in the United States.
Patrick Kelly: Chief Advocacy Officer, Healthcare Distribution Alliance
John Murphy: President and CEO, Association for Accessible Medicines

Across these conversations, they discuss how low prices, thin margins, supply chain disruption, reshoring pressure, biosimilar market dynamics, insurance design, and federal pricing policy shape access to generic and biosimilar medicines.

Key Topics:
Generic Economics: Low prices, thin margins, purchaser pressure, manufacturer exits.
Shortage Drivers: Demand spikes, facility shutdowns, sterile injectables, chemotherapy disruptions.
Tariffs and Reshoring: Domestic production costs, national security concerns, tariff pass-through, contract constraints.
Biosimilar Competition: Private-label programs, vertical integration, investment uncertainty, patient access.
Policy and Insurance: IRA redesign, MFN pricing, direct-to-consumer pathways, prescription benefit reform.

Opinions expressed are those of the speakers. Original podcasts published in October 2025. The Vital Health Podcast is a production of Vital Transformation LLC © 2026.

In this best-of edition of the Vital Health Podcast, we revisit two conversations <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> has with experts on the future of generic medicines, drug shortages, and supply chain risk in the United States.
<ul data-start="348" data-end="502">
<li data-section-id="mlchlg" data-start="348" data-end="426"><a href="https://www.linkedin.com/in/patrick-kelly-08427a8/">Patrick Kelly</a>: Chief Advocacy Officer, <a href="https://www.linkedin.com/company/hdma/">Healthcare Distribution Alliance</a></li>
<li data-section-id="wnfwxb" data-start="427" data-end="502"><a href="https://www.linkedin.com/in/john-murphy-iii-9b19ab1/">John Murphy</a>: President and CEO, <a href="https://www.linkedin.com/company/accessiblemeds/">Association for Accessible Medicines</a></li>
</ul>
Across these conversations, they discuss how low prices, thin margins, supply chain disruption, reshoring pressure, biosimilar market dynamics, insurance design, and federal pricing policy shape access to generic and biosimilar medicines.
Key Topics:
<ul data-start="760" data-end="1312">
<li data-section-id="1l363d" data-start="760" data-end="850">Generic Economics: Low prices, thin margins, purchaser pressure, manufacturer exits.</li>
<li data-section-id="j2s9a5" data-start="851" data-end="956">Shortage Drivers: Demand spikes, facility shutdowns, sterile injectables, chemotherapy disruptions.</li>
<li data-section-id="1gqfuvg" data-start="957" data-end="1083">Tariffs and Reshoring: Domestic production costs, national security concerns, tariff pass-through, contract constraints.</li>
<li data-section-id="1n5vcwb" data-start="1084" data-end="1199">Biosimilar Competition: Private-label programs, vertical integration, investment uncertainty, patient access.</li>
<li data-section-id="1jlakpo" data-start="1200" data-end="1312">Policy and Insurance: IRA redesign, MFN pricing, direct-to-consumer pathways, prescription benefit reform.</li>
</ul>
Opinions expressed are those of the speakers. Original podcasts published in October 2025. The Vital Health Podcast is a production of Vital Transformation LLC &copy; 2026.

Patrick Kelly & John Murphy: Generic Shortages and Supply Chain Risk

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Christopher Locher, Chief Executive Officer at Versatope Therapeutics, about the current landscape for vaccine manufacturers and innovators. Their conversation covers vaccine platform development, financing challenges for infectious disease companies, policy and regulatory uncertainty, the public health implications of changes to childhood immunization schedules, and the steps needed to rebuild trust in vaccination.

Key Topics:

Vaccine Platform Innovation: Nanoparticle technology, universal influenza vaccine development, multispecific targeting, infectious disease, and oncology applications.

Financing Challenges: Venture capital headwinds, NIH support, clinical development costs, grant cancellations, and startup survival pressures.

Policy Uncertainty: Changes to childhood immunization schedules, liability debates, academic licensing concerns, royalty proposals, and the biotech investment climate.

Public Health Risks: Vaccine access, childhood disease vulnerability, antimicrobial resistance, influenza complications, and consequences of fragmented immunization policy.

Trust Rebuilding: COVID backlash, transparency concerns, anti-science sentiment, provider-patient communication, rebuilding confidence in vaccines.

Opinions expressed are those of the speakers.

In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> speaks with <a href="https://www.linkedin.com/in/christopher-locher-biotech/">Christopher Locher</a>, Chief Executive Officer at <a href="https://www.linkedin.com/company/versatope/">Versatope Therapeutics</a>, about the current landscape for vaccine manufacturers and innovators. Their conversation covers vaccine platform development, financing challenges for infectious disease companies, policy and regulatory uncertainty, the public health implications of changes to childhood immunization schedules, and the steps needed to rebuild trust in vaccination.
Key Topics: 
<ul>
<li>Vaccine Platform Innovation: Nanoparticle technology, universal influenza vaccine development, multispecific targeting, infectious disease, and oncology applications. </li>
<li>Financing Challenges:&nbsp;Venture capital headwinds, NIH support, clinical development costs, grant cancellations, and startup survival pressures. </li>
<li>Policy Uncertainty: Changes to childhood immunization schedules, liability debates, academic licensing concerns, royalty proposals, and the biotech investment climate. </li>
<li>Public Health Risks: Vaccine access, childhood disease vulnerability, antimicrobial resistance, influenza complications, and consequences of fragmented immunization policy. </li>
<li>Trust Rebuilding:&nbsp;COVID backlash, transparency concerns, anti-science sentiment, provider-patient communication, rebuilding confidence in vaccines.</li>
</ul>
Opinions expressed are those of the speakers.

Christopher Locher: Why Vaccine Innovation Matters More Than Ever

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Melanie Whittington, Managing Director and Head of the Leerink Center for Pharmacoeconomics and Senior Fellow at the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center.

They examine how health economic modeling can more accurately reflect real-world market dynamics, the rising pressure behind IRA and MFN drug pricing, the risks to oncology innovation, the limits of conventional cost-effectiveness frameworks, plus the role of transparency and clearer communication of long-term value in sustaining a healthy innovation ecosystem.

Key Topics
Market Modeling: Hypothetical models versus real-world pricing dynamics, patent cliffs.
Pricing Policy: IRA, MFN, market-based pricing scrutiny, communicating why prices are "worth it".
Innovation Incentives: Private capital risk, oncology small molecules, policy-driven pipeline shifts.
Value Framework Limits: QALY concerns, rule-versus-tool debates, GRACE, broader treatment impacts.
Transparency and Outlook: Net price opacity, PBM negotiations, generics and biosimilars, the next innovation cycle.

Opinions expressed are those of the speakers. The Leerink Center for Pharmacoeconomics is a division of MEDACorp.

In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> speaks with <a href="https://www.linkedin.com/in/melanie-whittington/">Melanie Whittington</a>, Managing Director and Head of the Leerink Center for Pharmacoeconomics and Senior Fellow at the <a href="https://www.linkedin.com/company/cevr/">Center for the Evaluation of Value and Risk in Health at Tufts Medical Center</a>.
They examine how health economic modeling can more accurately reflect real-world market dynamics, the rising pressure behind IRA and MFN drug pricing, the risks to oncology innovation, the limits of conventional cost-effectiveness frameworks, plus the role of transparency and clearer communication of long-term value in sustaining a healthy innovation ecosystem.
Key Topics
<ul>
<li>Market Modeling: Hypothetical models versus real-world pricing dynamics, patent cliffs.</li>
<li>Pricing Policy: IRA, MFN, market-based pricing scrutiny, communicating why prices are "worth it".</li>
<li>Innovation Incentives: Private capital risk, oncology small molecules, policy-driven pipeline shifts.</li>
<li>Value Framework Limits: QALY concerns, rule-versus-tool debates, GRACE, broader treatment impacts.</li>
<li>Transparency and Outlook: Net price opacity, PBM negotiations, generics and biosimilars, the next innovation cycle.</li>
</ul>
Opinions expressed are those of the speakers. The Leerink Center for Pharmacoeconomics is a division of MEDACorp.

VT's Grumpies and Lady Discuss the U.S. Biotech Policy Landscape

In 1 playlist(s)

Vital Health Podcast

Social links

Follow podcast

Recent clips